Galen announces profits up 52% in Q4
Belfast-based pharmaceutical holding company Galen, has announced product revenues of $140.9m (€110.32m) and operating profits up 52% to $72.9m (€57.07m) for the first quarter to December 31, 2003.
Galen's largest segment is women's healthcare consisting of oestrogen replacement therapies, contraceptives, and prenatal vitamin supplements